Evidence map›Paper›PMID 39987413›Full record

Trial reportEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025

Comparative safety analysis of coseasonal versus preseasonal Artemisia annua sublingual immunotherapy for allergic rhinitis.

Ying Liu, Feng Chen, Ning Wang, Chan He, Chunyan Tian, Yan Feng, Hui HuangFu

Abstract readRandomized Controlled TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Efficacy and safety ofThe Journal of international medical research · 2026
    Observational
  2. Clinical outcomes of 2-yearAsia Pacific allergy · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ying LiuDepartment of Otolaryngology Head and Neck Surgery, The First Hospital, Shanxi Medical University, Taiyuan, China.
Feng ChenPulmonary and Critical Care Medicine Department, The First Hospital, Shan Medical University, Taiyuan, China.
Ning WangDepartment of Otolaryngology Head and Neck Surgery, The First Hospital, Shanxi Medical University, Taiyuan, China.
Chan HeDepartment of Otolaryngology Head and Neck Surgery, The First Hospital, Shanxi Medical University, Taiyuan, China.
Chunyan TianDepartment of Otolaryngology Head and Neck Surgery, The First Hospital, Shanxi Medical University, Taiyuan, China.
Yan FengDepartment of Otolaryngology Head and Neck Surgery, The First Hospital, Shanxi Medical University, Taiyuan, China. 15635131417@163.com.
Hui HuangFuDepartment of Otolaryngology Head and Neck Surgery, The First Hospital, Shanxi Medical University, Taiyuan, China. 13934518228@163.com.ORCID http://orcid.org/0000-0002-1763-1373

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePatients with seasonal allergic rhinitis (SAR) usually seek treatment when symptoms become unbearable during the pollen season. It remains unclear whether initiating sublingual immunotherapy (SLIT) during the pollen season affects patients' safety. This study aims to compare the tolerability of initiating Artemisia annua SLIT during the pollen season versus before the season.

methodsNinety patients with Artemisia-induced SAR were recruited and equally randomized into the coseasonal initiation treatment (COS-SLIT) group and the preseasonal initiation treatment (PRE-SLIT) group. The COS-SLIT group started SLIT when allergic symptoms occurred during the 2022 pollen season, while the PRE-SLIT group began SLIT four months before the expected season in 2022. Patients were categorized as mild symptoms or moderate-severe symptoms group based on the level of visual analog scale (VAS) scores evaluated during the 2021 pollen season. The incidence, frequency, performance, and alleviating measures of adverse events (AEs) were analyzed after the up-dosing phase (5 weeks), at three months (13 weeks), six months (26 weeks), and twelve months (52 weeks).

resultsA total of 72 patients (32 patients in the COS-SLIT group and 40 patients in the PRE-SLIT) were included in the analysis. Among these patients, 33 reported a total of 78 AEs. No significant difference was found in the frequency and number of patients experiencing AEs between the COS-SLIT and PRE-SLIT groups during the four follow-up periods (all p > 0.05). There were no significant differences in the symptoms or alleviating measures of AEs between the two groups in general (all p > 0.05). Furthermore, the most common AEs in the COS-SLIT group were nasal symptoms (n = 14), lip edema (n = 10), and cough (n = 4), while in the PRE-SLIT group were nasal symptoms (n = 12), lip edema (n = 8), and ocular pruritus (n = 6). Symptomatic drugs were the most common alleviating measures in both groups (61.29% in COS-SLIT and 64.52% in PRE-SLIT, p > 0.05). Patients with mild and moderate-severe symptoms showed comparable tolerability at different initiation timing (all p > 0.05).

conclusionThis prospective study demonstrates the comparable safety and tolerability of initiating Artemisia annua SLIT during the pollen season and before the season.

Indexed as

Artemisia annuaRhinitis, Allergic, SeasonalSublingual ImmunotherapyAdolescentAdultAllergensFemaleHumansMaleMiddle AgedPollenTreatment OutcomeYoung AdultAllergensAeroallergensAllergic rhinitisArtemisiaCoseasonal initiationSeasonal allergic rhinoconjunctivitisSublingual immunotherapy

Identifiers

PMID39987413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.